VOYA Investment Management
LCTX icon

VOYA Investment Management’s Lineage Cell Therapeutics LCTX Stock Holding History

VOYA Investment Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.8K Buy
+37,232
New +$51.5K ﹤0.01% 2457
2025
Q2 		– Sell
-38,835
Closed -$17.5K – 2701
2025
Q1 		$17.5K Hold
38,835
– – ﹤0.01% 2629
2024
Q4 		$19.5K Sell
38,835
-17,951
-32% -$13.2K ﹤0.01% 2729
2024
Q3 		$51.4K Hold
56,786
– – ﹤0.01% 2771
2024
Q2 		$56.6K Buy
56,786
+8,956
+19% +$9.89K ﹤0.01% 2780
2024
Q1 		$70.8K Sell
47,830
-8,765
-15% -$9.94K ﹤0.01% 2685
2023
Q4 		$61.7K Hold
56,595
– – ﹤0.01% 2830
2023
Q3 		$66.8K Hold
56,595
– – ﹤0.01% 2817
2023
Q2 		$79.8K Buy
+56,595
New +$78.2K ﹤0.01% 2845
2022
Q2 		– Sell
-47,315
Closed -$73K – 2839
2022
Q1 		$73K Hold
47,315
– – ﹤0.01% 2555
2021
Q4 		$116K Sell
47,315
-655
-1% -$1.53K ﹤0.01% 2644
2021
Q3 		$121K Hold
47,970
– – ﹤0.01% 2699
2021
Q2 		$137K Buy
+47,970
New +$124K ﹤0.01% 2699
2020
Q2 		– Sell
-59,324
Closed -$49K – 2561
2020
Q1 		$49K Sell
59,324
-12,401
-17% -$12.3K ﹤0.01% 2493
2019
Q4 		$64K Buy
71,725
+25,491
+55% +$21.2K ﹤0.01% 2620
2019
Q3 		$45K Hold
46,234
– – ﹤0.01% 2513
2019
Q2 		$51K Hold
46,234
– – ﹤0.01% 2562
2019
Q1 		$61K Buy
46,234
+13,738
+42% +$17.1K ﹤0.01% 2497
2018
Q4 		$30K Sell
32,496
-4,647
-13% -$7.12K ﹤0.01% 2526
2018
Q3 		$76K Hold
37,143
– – ﹤0.01% 2530
2018
Q2 		$67K Hold
37,143
– – ﹤0.01% 2580
2018
Q1 		$87K Hold
37,143
– – ﹤0.01% 2496
2017
Q4 		$70K Hold
37,143
– – ﹤0.01% 2546
2017
Q3 		$92K Hold
37,143
– – ﹤0.01% 2556
2017
Q2 		$102K Buy
37,143
+10,282
+38% +$28.7K ﹤0.01% 2564
2017
Q1 		$81K Buy
+26,861
New +$76.3K ﹤0.01% 2452

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

VOYA Investment Management's LCTX Position: Q2 2026 in Review

VOYA Investment Management opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 37,232 shares worth $48.8K. The stake represents ﹤0.01% of the portfolio and ranks #2457 among its holdings. This is a return to the name: VOYA Investment Management previously reported a position in LCTX as recently as Q1 2025.

VOYA Investment Management first reported a position in LCTX in Q1 2017 and has held it in 26 quarters since. The position peaked at $137K in Q2 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • VOYA Investment Management held 37,232 shares of Lineage Cell Therapeutics worth $48.8K as of Q2 2026.
  • Lineage Cell Therapeutics was a new VOYA Investment Management position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of VOYA Investment Management's portfolio in Q2 2026, its #2457 holding.
  • VOYA Investment Management first reported a position in Lineage Cell Therapeutics in Q1 2017 and has held it in 26 quarters since.
  • VOYA Investment Management's Lineage Cell Therapeutics position peaked at $137K in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on VOYA Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.